Your web browser is out of date.
For your security and improved experience online, please update your browser.
Date of publication:
Metformin is the first-line drug of choice in the treatment of type 2 diabetes in most diabetes guidance. Last year the European Medicines Agency (EMA) altered the restrictions on metformin use in people with diabetes and researchers wanted to discover, in the absence of prospective safety and efficacy studies, what was a safe, effective dose regimen for metformin in moderate and severe chronic kidney disease (CKD). Investigators concluded that metformin appeared to be safe, provided that there was dose adjustment for renal function. It was also found to be efficacious in moderate-to-severe CKD.
Sign up to all DiabetesontheNet journals
This website is for UK healthcare professionals only. To continue, please confirm that you are a UK healthcare professional below.